A Study of IBI362 in Chinese Patients With Type 2 Diabetes
A Randomized Phase II Study to Evaluate the Efficacy and Safety of IBI362 Versus Placebo and Dulaglutide in Chinese Patients With Type 2 Diabetes
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Listed as NCT04965506, this PHASE2 trial focuses on Type 2 Diabetes and remains completed. Sponsored by Innovent Biologics (Suzhou) Co. Ltd., it has been updated 6 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2022 — Jan 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
Status: Not Yet Recruiting → Active Not Recruiting
▶ Show 1 earlier version
-
Sep 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Innovent Biologics (Suzhou) Co. Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .